Omeprazole and its cousins: when the acid drug is quietly too weak or too strong
Proton pump inhibitors are among the most-taken drugs on earth, so a common gene that shifts how much of them reaches the blood is not a curiosity. It changes whether the tablet is doing enough, or more than it needs to, for a very large number of people.
This page also covers lansoprazole, pantoprazole: CPIC publishes one recommendation for them all, so the guidance below applies to each of them.
Also sold as: Prilosec, Losec, Prevacid, Protonix, Somac.
What omeprazole, lansoprazole and pantoprazole are
Omeprazole, lansoprazole and pantoprazole are proton pump inhibitors, or PPIs. They shut down acid production in the stomach and are used for reflux, for ulcers, and to clear Helicobacter pylori infection. They are sold over the counter in many countries and taken for years by a lot of people, sometimes with less review than a long-running drug deserves.
Why your genes come into it
CYP2C19 is the main enzyme that clears these three PPIs, and how fast it works decides the blood level a given dose produces. Slow metabolizers hold onto the drug longer, so a standard dose gives them more acid suppression than the label assumes, which for long-term use can be more than they need. Rapid and ultrarapid metabolizers do the opposite: they clear the drug quickly, so a standard dose can leave acid suppression short of what the condition requires, and that shortfall shows up most where the target is demanding, such as eradicating H. pylori or healing an inflamed oesophagus. Both directions have published guidance, which is unusual and part of why this drug class is a clean example of the gene mattering in ordinary care.
What published guidance says
The rows below restate CPIC's published guidance for each possible CYP2C19 result. They describe how a prescriber might tune a dose, not a change to make on your own. A PPI is often being taken for a reason that would return if it stopped, and long-term acid suppression has its own considerations that a genotype does not settle, so this is context for a conversation rather than an instruction.
CYP2C19
| If your CYP2C19 result is | What that means | Published CPIC guidance |
|---|---|---|
| Intermediate Metabolizer | Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity | Per CPIC (A): "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy." |
| Likely Intermediate Metabolizer | Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity | Per CPIC (A): "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy." |
| Likely Poor Metabolizer | Likely increased plasma concentration of PPI compared to CYP2C19 NMs; likely increased chance of efficacy and potentially toxicity | Per CPIC (A): "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy." |
| Normal Metabolizer | Normal PPI metabolism; may be at increased risk of therapeutic failure compared to CYP2C19 IMs and PMs | Per CPIC (A): "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy." |
| Poor Metabolizer | Increased plasma concentration of PPI compared to CYP2C19 NMs; increased chance of efficacy and potentially toxicity | Per CPIC (A): "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy." |
| Rapid Metabolizer | Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure | Per CPIC (A): "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses. Monitor for efficacy." |
| Ultrarapid Metabolizer | Decreased plasma concentrations of PPIs compared to CYP2C19 NMs; increased risk of therapeutic failure | Per CPIC (A): "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy." |
Can your DNA file answer this?
CYP2C19 is one of the pharmacogenes a consumer chip file can genuinely answer, so a PPI question is a useful one to bring to an existing 23andMe or AncestryDNA export. The common reduced-function *2 and increased-function *17 alleles are single positions that consumer arrays generally carry. Rarer alleles are not, and read as reference; where a defining position is missing the report says the genotype is unconfirmed rather than assuming the common result, and an unresolved star-allele call comes back as Indeterminate. One honest limit on the drug side: this page covers omeprazole, lansoprazole and pantoprazole because their guidance is identical, but not every PPI clears the same way, so a result here does not automatically transfer to a different one such as dexlansoprazole.
A genotyping chip reads only a few hundred thousand pre-selected positions, about 0.02% of your genome, chosen for common variation. It does not sequence the rest, so it cannot find the rare or novel pathogenic variants the clinical and carrier modules look for: a “no finding” from chip data means “this chip never looked”, far more so than with whole-genome sequencing. Chip data suits common-variant traits, pharmacogenomic tag SNPs, and haplogroup ancestry, not clinical or carrier screening.
Common questions
My reflux drug does not seem to help. Could my genes explain it?
It is one possible thread. If you clear CYP2C19 substrates quickly, a standard PPI dose can produce a lower blood level than the label assumes, which reads as the drug underperforming. It is far from the only explanation, though, since dose timing, diet and the underlying cause all matter, so a result is a reason to raise the question with a prescriber rather than an answer by itself.
Why are three different PPIs on one page?
Because CPIC publishes the same CYP2C19 guidance for omeprazole, lansoprazole and pantoprazole, and the site verifies that the recommendation text matches exactly before merging them. Splitting them would produce near-identical pages, which is worse for a reader. Not every PPI qualifies: dexlansoprazole has different guidance and is deliberately left off this page.
I take omeprazole and clopidogrel together. Is that a problem?
It is a recognised prescribing question rather than an internet rumour, because both drugs involve CYP2C19, and some pairings are avoided for that reason. It is separate from your own genotype and belongs on your medication list in front of the prescriber or pharmacist who can see everything you take.
Can I use my old 23andMe file for this?
For CYP2C19, usually yes, which makes a PPI one of the better-answered questions from consumer data. Aimosti reads the file you already own rather than selling a new test, and where the file does not resolve your star alleles it reports Indeterminate instead of assuming the common result.